245 related articles for article (PubMed ID: 36074682)
21. Brain lesions in tuberous sclerosis complex. Review.
Grajkowska W; Kotulska K; Jurkiewicz E; Matyja E
Folia Neuropathol; 2010; 48(3):139-49. PubMed ID: 20924998
[TBL] [Abstract][Full Text] [Related]
22. Association between the growth rate of subependymal giant cell astrocytoma and age in patients with tuberous sclerosis complex.
Tsai JD; Wei CC; Tsao TF; Hsiao YP; Tsai HJ; Yang SH; Tsai ML; Sheu JN
Childs Nerv Syst; 2016 Jan; 32(1):89-95. PubMed ID: 26552385
[TBL] [Abstract][Full Text] [Related]
23. Dose-level response rates of mTor inhibition in tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
Weidman DR; Pole JD; Bouffet E; Taylor MD; Bartels U
Pediatr Blood Cancer; 2015 Oct; 62(10):1754-60. PubMed ID: 25929843
[TBL] [Abstract][Full Text] [Related]
24. Solitary subependymal giant cell astrocytoma: Case report and review of the literature.
Corlette L; Reid A; Roberts-Thomson S; Christie M; Gaillard F
J Clin Neurosci; 2020 Dec; 82(Pt A):26-28. PubMed ID: 33317733
[TBL] [Abstract][Full Text] [Related]
25. A case of subependymal giant cell astrocytoma without tuberous sclerosis complex and review of the literature.
O'Rawe M; Chandran AS; Joshi S; Simonin A; Dyke JM; Lee S
Childs Nerv Syst; 2021 Apr; 37(4):1381-1385. PubMed ID: 32808065
[TBL] [Abstract][Full Text] [Related]
26. Subependymal giant cell astrocytoma: a lesion with activated mTOR pathway and constant expression of glutamine synthetase.
Buccoliero AM; Caporalini C; Giordano F; Mussa F; Scagnet M; Moscardi S; Baroni G; Genitori L; Taddei GL
Clin Neuropathol; 2016; 35(5):295-301. PubMed ID: 27390104
[TBL] [Abstract][Full Text] [Related]
27. Magnetic resonance imaging diagnosis of subependymal giant cell astrocytomas in follow-up of children with tuberous sclerosis complex: should we always use contrast enhancement?
Gaillard AL; Crombé A; Jecko V; Bessou P; Havez M; Pédespan JM; Van Gils J; Chateil JF
Pediatr Radiol; 2020 Sep; 50(10):1397-1408. PubMed ID: 32671416
[TBL] [Abstract][Full Text] [Related]
28. Experience using mTOR inhibitors for subependymal giant cell astrocytoma in tuberous sclerosis complex at a single facility.
Tomoto K; Fujimoto A; Inenaga C; Okanishi T; Imai S; Ogai M; Fukunaga A; Nakamura H; Sato K; Obana A; Masui T; Arai Y; Enoki H
BMC Neurol; 2021 Mar; 21(1):139. PubMed ID: 33784976
[TBL] [Abstract][Full Text] [Related]
29. Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients.
Kotulska K; Borkowska J; Roszkowski M; Mandera M; Daszkiewicz P; Drabik K; Jurkiewicz E; Larysz-Brysz M; Nowak K; Grajkowska W; Domańska-Pakieła D; Jóźwiak S
Pediatr Neurol; 2014 Apr; 50(4):307-12. PubMed ID: 24507694
[TBL] [Abstract][Full Text] [Related]
30. Pathological Findings of a Subependymal Giant Cell Astrocytoma Following Treatment With Rapamycin.
Cheng S; Hawkins C; Taylor MD; Bartels U
Pediatr Neurol; 2015 Sep; 53(3):238-242.e1. PubMed ID: 26173783
[TBL] [Abstract][Full Text] [Related]
31. Juvenile xanthogranuloma as a new type of skin lesions in tuberous sclerosis complex.
Lu Q; Shi XY; Wang YY; Zhang MN; Wang WZ; Wang J; Wang QH; Chen HM; Zou LP
Orphanet J Rare Dis; 2020 Jun; 15(1):147. PubMed ID: 32532290
[TBL] [Abstract][Full Text] [Related]
32. Fetal brain lesions in tuberous sclerosis complex: TORC1 activation and inflammation.
Prabowo AS; Anink JJ; Lammens M; Nellist M; van den Ouweland AM; Adle-Biassette H; Sarnat HB; Flores-Sarnat L; Crino PB; Aronica E
Brain Pathol; 2013 Jan; 23(1):45-59. PubMed ID: 22805177
[TBL] [Abstract][Full Text] [Related]
33. Subependymal giant cell astrocytoma in the absence of tuberous sclerosis: illustrative case.
Shelley I; Mahtabfar A; Farrell CJ
J Neurosurg Case Lessons; 2023 Jun; 5(25):. PubMed ID: 37354433
[TBL] [Abstract][Full Text] [Related]
34. A Bama miniature pig model of monoallelic TSC1 mutation for human tuberous sclerosis complex.
Li X; Hu T; Liu J; Fang B; Geng X; Xiong Q; Zhang L; Jin Y; Liu X; Li L; Wang Y; Li R; Bai X; Yang H; Dai Y
J Genet Genomics; 2020 Dec; 47(12):735-742. PubMed ID: 33612456
[TBL] [Abstract][Full Text] [Related]
35. New developments in the neurobiology of the tuberous sclerosis complex.
Crino PB; Henske EP
Neurology; 1999 Oct; 53(7):1384-90. PubMed ID: 10534239
[TBL] [Abstract][Full Text] [Related]
36. Tuberous sclerosis complex presenting as convulsive status epilepticus followed by hypoxic cerebropathy: A case report.
Liu X; Zhang Y; Hao Y; Chen Y; Chen C
Medicine (Baltimore); 2019 May; 98(19):e15545. PubMed ID: 31083211
[TBL] [Abstract][Full Text] [Related]
37. Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Clinical recommendations.
Jóźwiak S; Nabbout R; Curatolo P;
Eur J Paediatr Neurol; 2013 Jul; 17(4):348-52. PubMed ID: 23391693
[TBL] [Abstract][Full Text] [Related]
38. Significant cases of central cusps, enamel pits, and oral fibromas in tuberous sclerosis complex.
Taga H; Yonenaga K; Eno Y; Yasumitsu T; Hatano T; Matsuo A; Takato T
Odontology; 2021 Jan; 109(1):279-283. PubMed ID: 32720211
[TBL] [Abstract][Full Text] [Related]
39. Identification of TSC1 or TSC2 mutation limited to the tumor in three cases of solitary subependymal giant cell astrocytoma using next-generation sequencing technology.
Fohlen M; Harzallah I; Polivka M; Giuliano F; Pons L; Streichenberger N; Dorfmüller G; Touraine R
Childs Nerv Syst; 2020 May; 36(5):961-965. PubMed ID: 32103336
[TBL] [Abstract][Full Text] [Related]
40. Deep phenotyping of patients with Tuberous Sclerosis Complex and no mutation identified in TSC1 and TSC2.
Peron A; Vignoli A; Briola F; Morenghi E; Tansini L; Alfano RM; Bulfamante G; Terraneo S; Ghelma F; Banderali G; Viskochil DH; Carey JC; Canevini MP;
Eur J Med Genet; 2018 Jul; 61(7):403-410. PubMed ID: 29432982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
